Breaks Categories: Stock Spotlights

MondayMay 03, 2021 12:51 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Eyes Rapid Progress to Clinical Studies for Psychedelic Drug Candidates

Cybin (NEO: CYBN) (OTCQB: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, has completed key in-vitro and in-vivo research studies. The company recently announced completion of its 20th pre-clinical study and the progression of two psychedelic drug candidates: CYB003 and CYB004. According to Cybin, the studies were completed in record time, in part due to close collaboration with the company’s partners and contractors. “Excellent teamwork and fully supportive partners have greatly facilitated the advancement of these two new therapeutic candidates with enhanced and improved properties,” said Michael Palfreyman, Cybin’s chief R&D officer, in a…

Continue Reading

MondayApr 19, 2021 1:36 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) to Bring Quality Products to Retail Buyers Across Canada

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), through its wholly owned subsidiary, Pure Extracts Manufacturing Corp., recently entered into a distribution agreement with an important Canadian LP. Under the agreement, the LP will sell Pure Extracts’ exclusive, high-quality cannabis extract products to provincially authorized distributors and retailers throughout Canada by the end of April. In addition, Pure Extracts has submitted an application to Health Canada to amend its license to permit the company itself to sell cannabis extract products to provincially authorized distributors and retailers. “This milestone dovetails perfectly with our recently signed distribution agreement,” said Pure Extracts’…

Continue Reading

ThursdayApr 15, 2021 11:38 am

PsychedelicNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) ‘Covid-ID Lab’ Combines Speed of Rapid Screening with Accuracy of PCR Diagnostic

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, is set to launch a solution for improving detection of the virus responsible for the worldwide pandemic. The company recently announced European regulatory approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system. Known as “Covid-ID Lab,” the system is a commercial in-vitro diagnostic device (CE-IVD) designed to help industry professionals and government agencies screen for the virus. XPhyto’s exclusive German diagnostics partner, 3a-diagnostics GmbH, developed Covid-ID Lab to provide rapid, accurate and portable testing capabilities, granting it marketability as a product with increased convenience and decreased operating costs.…

Continue Reading

WednesdayMar 24, 2021 2:23 pm

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Working to Expand Test Portfolio

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), which recently received European approval for its COVID-19 rapid and portable test system, has set out to increase its portfolio of tests for different diseases to help fight the current and potential pandemics. XPhyto has partnered with Germany’s 3a-diagnostics GmbH for this, according to an article on the company’s recent announcements. “The company is also working with 3a to develop a portfolio of oral biosensor screening tests that detect bacterial and viral infectious diseases ranging from influenza A to group A strep, as well as focusing on other potential pandemic biosensor tech…

Continue Reading

FridayFeb 19, 2021 1:59 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTC: CLXPF) to Leverage Breakthrough Tech to Measure Real-Time Brain Activity During Psychedelic Experiences

Cybin (NEO: CYBN) (OTC: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently announced its collaboration with neurotech pioneer HI LLC dba Kernel. According to the update, CYBN will leverage Kernel Flow, Kernel’s breakthrough technology, for its upcoming clinical work to quantify brain activity in real time during psychedelic experiences. “Access to Kernel’s innovative Flow technology adds another exciting dimension to the investigative work that Cybin is doing to develop breakthrough treatments for mental health disorders such as depression and addiction,” said Cybin CEO Doug Drysdale in a recent update. “Currently, clinical investigators rely…

Continue Reading

FridayFeb 05, 2021 3:04 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) Positioned Amid Growing Acceptance, Legalization of Psilocybin

Cybin (NEO: CYBN) is a mushroom life science company focused on the pharmaceutical development of psychedelic products. Cybin’s subsidiary Serenity Life Sciences is engaged in the research and development of psilocybin-based medications. Widely referred to as magic mushrooms, Psilocybin has had its share of bad press. However, the company is positioned as perceptions of this substance are beginning to change. A recent article discussing this reads, “Under the Controlled Substances Act, psilocybin is included with heroin and LSD as a Schedule I drug. According to the National Drug Intelligence Center, psilocybin serves no legitimate medical purpose in the United States.…

Continue Reading

FridayJan 29, 2021 2:55 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) Poised to Provide Breakthrough Therapy for MDD

Cybin (NEO: CYBN), a mushroom life science company, is at the forefront of new treatments targeting major depressive disorder (“MDD”). The company is working to become the first to bring a psilocybin drug to market that targets MDD. This positions Cybin to provide solutions amid significant demand, with more than 18 million people in the United States and 300 million people worldwide who experience major depression according to the National Institute of Mental Health. A recent article discussing this reads, “Since 2018, the FDA has labeled psychedelic psilocybin a ‘breakthrough therapy’ to treat MDD. This designation fast tracks the substance…

Continue Reading

TuesdayJan 12, 2021 1:45 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) Leverages Key Experience, Prepares Entry into Psychedelic Mushroom Market

Pure Extracts (CSE: PULL), a plant-based extraction company, is focused on cannabis, hemp, and functional mushroom sectors, the last of which is projected to rise to a value of $34.4 billion by the end of 2024. Seeking to capitalize on the growing interest within the sector, Pure Extracts has expanded its business model to include mushroom formulations using extraction processes proven compatible with the company’s existing infrastructure. Working alongside its scientific advisor—Dr. Alexander MacGregor, founder of the Toronto Institute of Pharmaceutical Technology—Pure Extracts intends to develop high bio-available products and novel delivery methodologies, which will include tinctures, pills, capsules and…

Continue Reading

MondayDec 28, 2020 2:22 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) on Track to Leverage Psychedelics to Target Depression

Cybin (NEO: CYBN), a mushroom life science company, is set to leverage opportunity amid growing research that demonstrates the significant role psilocybin could play in alleviating symptoms of major depression. According to a recent study conducted by Johns Hopkins Medicine and published in “JAMA Psychiatry,” only two doses of psilocybin accompanied with psychotherapy may lead to significant reductions in symptoms in adults with major depression (https://ibn.fm/ZpmzM). “The magnitude of the effect we saw was about four times larger than what clinical trials have shown for traditional antidepressants on the market,” stated Alan Davis, PhD., adjunct assistant professor of psychiatry and…

Continue Reading

WednesdayDec 23, 2020 2:08 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) Looks to Play ‘Pivotal Role’ in Supply Chain

Pure Extracts (CSE: PULL), a plant-based extraction company focused on cannabis, hemp and functional mushroom sectors, recently began trading on the Canadian Securities Exchange (“CSE”) under the symbol “PULL.” Pure Extracts leverages proprietary CO2 extraction methodology to obtain full-spectrum oil (“FSO”) from cannabis and hemp biomass. “We are pleased to have listed on the Canadian Securities Exchange as a significant first step towards Pure Extracts’ continual expansion within the emerging extraction space,” said Pure Extracts’ CEO Ben Nikolaevsky in a recent update. “There currently is a tremendous opportunity for growth in consumer natural health products, for which we plan on…

Continue Reading